Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04853160 · ClinicalTrials.gov registry record
Drug Use Study of Febuxostat After Recent Changes in the Prescribing Information
A clinical trial, sponsored by Takeda.
- Completed
- Registry status
- 24,046
- Enrollment target
NCT04853160: Completed study, sponsored by Takeda.
NCT04853160 is a clinical trial that has completed, run by Takeda. The registered enrollment target is 24,046 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04853160 has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- 24,046 participants
- Enrollment target
Study Summary
The prescribing information provides information on medicines. This study will check the number of patients starting febuxostat and the number of febuxostat users with cardiovascular disease after changes to the prescribing information.
Primary Outcome
Participants will be categorized into new users and prevalent new users. New users are participants who were naïve to allopurinol, defined as no record of allopurinol use in all historic pharmacy or medical claims at any time prior to initiation of febuxostat. Prevalent new users are participants who had used allopurinol and switched, defined as at least one record of allopurinol use in all historic pharmacy or medical claims at any time prior to initiation of febuxostat.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24,046 participants |
| Start Date | 2020-08-15 |
| Est. Completion | 2021-01-05 |
What the finished NCT04853160 record still lists
NCT04853160 is an observational study that tracks outcomes without assigning an intervention. Its 24,046 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT04853160 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04853160 about?
NCT04853160 is a clinical study titled "Drug Use Study of Febuxostat After Recent Changes in the Prescribing Information". The prescribing information provides information on medicines. This study will check the number of patients starting febuxostat and the number of febuxostat users with cardiovascular disease after changes to the prescribing information.
What is the current status of trial NCT04853160?
This trial is currently completed. The enrollment target is 24,046 participants. The study started on 2020-08-15. Estimated completion is 2021-01-05.
Who is sponsoring clinical trial NCT04853160?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06995898 · 24,000 participants · NA
The Vanguard Study: Testing a New Way to Screen for Cancer
- NCT04595201 · 25,000 participants
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
- NCT04994015 · 25,000 participants
Parkinson's Foundation PD GENEration Genetic Registry
- NCT06589310 · 25,000 participants
Falcon Real World Evidence Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI